SCHEMBL25686054

SCHEMBL25686054

CC1CC(C)CN(c2ccc(Br)cn2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.51
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
ACACB O00763 1/20 0.43
PDE10A Q9Y233 1/20 0.42
AKR1C3 P42330 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.39
PANK3 Q9H999 1/20 0.38
OGA O60502 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.36
POLB P06746 1/20 0.35
CXCR3 P49682 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22796105 0.87 GRIN2D (0.43) CNR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21861463 0.83 MAPT (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14347211 0.83 MAPT (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13984216 0.83 MAPT (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29782885 0.82 GRIN2D (0.47) CNR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17610078 0.82 GRIN2D (0.47) CNR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17128293 0.81 HDAC1 (0.46) CNR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11359952 0.81 KMT2A (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL17803130 0.81 KMT2A (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29914603 0.81 KMT2A (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
US-11684625-B2 Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates AC IMMUNE SA (CH) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B CNR2 3527/4885GRIN2D 769/4885GRIN3B 292/4885
US-11684625-B2 Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates MAPT, PSEN2, PSEN1 CNR2 3589/4885GRIN2D 662/4885GRIN3B 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.